UT-XLEAR
16.5.2022 16:02:14 CEST | Business Wire | Press release
Today Xlear announced a new partnership with Dr. Ferrer BioPharma (DFBP), which will make Xlear nasal spray the first nasal hygiene tool to deploy the GentleMist nozzle—the next generation nasal spray technology that research shows achieves better compound dispersion and coverage and a better user experience.
Nasal cleansing studies have found that rinsing the nose and nasal cavity is an important tool for improving health and wellbeing. Numerous clinical and lab studies have found that nasal hygiene is an important adjunct in countering rhinositus, as well as a range of bacterial and viral infections.
New research, published by The European Society of Medicine found that the GentleMist nozzle achieved more uniform and more complete dispersion of nasal sprays into the nose and nasal cavity. The study also found that the new nozzle was gentler and significantly improved the user experience over typical nose spray technologies. You can read the full study by clicking here: Evaluation of Patient Experience for a Computationally-Guided Intranasal Spray Protocol to Augment Therapeutic Penetration: Implications for Effective Treatments for COVID-19, Rhinitis, and Sinusitis | Medical Research Archives (esmed.org)
Traditionally nasal sprays have just had a standard pattern where the spray shoots straight up the airway in the direction it is sprayed. The new nozzle is very gentle and the spray is applied in a vortex/whirlpool pattern. This is extremely important and beneficial for Xlear and their customers as it allows Xlear’s mix (saline, xylitol and grapefruit seed extract) to be applied much more effectively and completely to the nose and nasal cavity.
“For more than twenty years, millions of people have been using and benefiting from our nasal spray and we are extremely excited to make this new technology available to them to improve their user experience. We realize that if washing our nose every morning and evening is uncomfortable, or irritating or hurts in even the slightest way we are not going to have people wash their nose enough to where it will make a difference. If it hurt us every time we washed our hands…or brushed our teeth, we wouldn’t be doing that enough either. Just like washing our hands, taking a shower and brushing our teeth, washing our nose is an added layer of protection to keeping us clean and healthy…and breathing better all day,” said Xlear CEO Nate Jones.
Xlear is not intended to diagnose, treat, cure or prevent any disease.
About Xlear
Founded in 2000, Xlear, Inc. is recognized as the leading manufacturer of natural, proactive health care products with xylitol. Xlear is committed to providing consumers with the highest quality products while striving to educate medical and dental professionals, as well their patients, about how using xylitol instead of sugar can help people live a much healthier and happy life. Xlear is supported by a team of doctors, hygienists and scientists who advocate the use and benefits of xylitol through continuous clinical research. Xlear, Inc. offers Xlear Nasal Spray, an award-winning, patented saline and xylitol nasal solution; a complete line of oral health products offered under the Spry Dental Defense System; and Lite&Sweet, a xylitol and erythritol sweetener used as a sugar substitute in cooking, baking and general consumption. For more information visit www.xlear.com .
About Dr. Ferrer BioPharma
Dr. Ferrer BioPharma are the leading innovators in intranasal medications to treat cough, colds, flu, and allergies. Dr. Ferrer BioPharma uses advanced nanoparticle technology to bring high-quality, evidence-based, consumer-focused, and doctor-invented products to the market. The mission is to provide to the market evidence-based therapies combining new ideas with proven concepts in the service of helping people. From molecules to the delivery of effective therapies to treat the populations we serve, Dr. Ferrer Biopharma is designing top-of-the-line intranasal treatments to help people breathe better. For more information visit www.drferrerbiopharma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220516005266/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom